Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 5, 2013, Pages 1183-1190

  Layman, Rachel M ^a   Ruppert, Amy S ^b   Lynn, Melinda ^d   Mrozek, Ewa ^a   Ramaswamy, Bhuvaneswari ^a   Lustberg, Maryam B ^a   Wesolowski, Robert ^a   Ottman, Susan ^b   Carothers, Sarah ^b   Bingman, Anissa ^b   Reinbolt, Raquel ^c   Kraut, Eric H ^b   Shapiro, Charles L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Bendamustine; Erlotinib; Lymphopenia; Metastatic breast cancer; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; ERLOTINIB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INFECTION; LEUKOPENIA; LUNG DISEASE; LYMPHOCYTOPENIA; METABOLIC DISORDER; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOPENIA; MIDDLE AGED; NEOPLASM METASTASIS; NITROGEN MUSTARD COMPOUNDS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 84877926552     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2112-2     Document Type: Article

References (29)

1. Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376
2. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657
3. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52:108-118
4. Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25-32
5. Hoffken K, Merkle K, Schonfelder M et al (1998) Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 124:627-632
6. Reichmann U, Bokemeyer C, Wallwiener D et al (2007) Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. Ann Oncol 18:1981-1984
7. von Minckwitz G, Chernozemsky I, Sirakova L et al (2005) Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 16:871-877
8. Zulkowski K, Kath R, Semrau R et al (2002) Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 128:111-113
9. Leoni LM, Bailey B, Reifert J et al (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14:309-317
10. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235-244
11. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374
12. Reis-Filho JS, Milanezi F, Steele D et al (2006) Metaplastic breast carcinomas are basal-like tumours. Histopathology 49:10-21
13. Reis-Filho JS, Milanezi F, Carvalho S et al (2005) Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 7:R1028-R1035
14. Graham DL, Hillman DW, Hobday TJ et al (2005) N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or-second line therapy for metastatic breast cancer (MBC). J Clin Oncol 23, Abstract #644
15. Kaur H, Silverman P, Singh D et al (2006) Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). J Clin Oncol 24, Abstract#10623
16. Thome S, Hobday T, Hillman D et al (2007) Translational correlates, including outcome for patients with ER-/PR-/HER2- (triple neg (Tneg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for patients with previously treated metastatic breast cancer (MBC). J Clin Oncol 25, Abstract #1071
17. Twelves C, Trigo JM, Jones R et al (2008) Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 44:419-426
18. Solit DB, She Y, Lobo J et al (2005) Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 11:1983-1989
19. Mahaffey CM, Davies AM, Lara PN Jr et al (2007) Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 8:548-553
20. Gumerlock PH, Pryde BJ, Kimura T et al (2003) Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 22, Abstract #2661
21. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
22. Knauf WU, Lissichkov T, Aldaoud A et al (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384
23. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
24. Kahl BS, Bartlett NL, Leonard JP et al (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 116:106-114
25. Kath R, Blumenstengel K, Fricke HJ et al (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48-54
26. Schoffski P, Seeland G, Engel H et al (2000) Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol 11:729-734
27. Klippstein A, Schneider CP, Sayer HG et al (2003) Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol 129:316-319
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
29. Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552